Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06692712 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.

Study acronym: SPG50
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date changed from estimate of Feb 1, 2026 to Apr 1, 2026
    • Eligibility criteria expanded, about 179 words
    v3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 6 more changesShow less
    • Start date: Mar 1, 2025 to Feb 1, 2026
    • Study sites: 0 to 2
    • Eligibility criteria shortened, about 237 words
    • Secondary endpoints revised (6)
    • Collaborators expanded, about 11 words
    • Study title shortened, about 19 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase 3, open-label study to assess the efficacy and safety of a single lumbar intrathecal administration of MELPIDA in individuals with Hereditary Spastic Paraplegia Type 50 (SPG50).
Trial Details
NCT Number NCT06692712
Lead Sponsor Elpida Therapeutics SPC
Collaborators: University of Texas Southwestern Medical Center, Hospital Sant Joan de Deu
Conditions
(from sponsor)		 Hereditary Spastic Paraplegia Type 50
Related terms Paraplegia
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov